| Discovery of the Macrocycle 11-(2-Pyrrolidin-1-yl-ethoxy)-14, 19-dioxa-5, 7, 26-triaza-tetracyclo [19.3. 1.1 (2, 6). 1 (8, 12)] heptacosa-1 (25), 2 (26), 3, 5, 8, 10, 12 (27 … AD William, ACH Lee, S Blanchard, A Poulsen, EL Teo, H Nagaraj, E Tan, ... Journal of medicinal chemistry 54 (13), 4638-4658, 2011 | 203 | 2011 |
| Analysis of five HMG-CoA reductase inhibitors-- atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin: pharmacological, pharmacokinetic and analytical overview … SNR Pasha MK, Muzeeb S, Basha SJ, Shashikumar D Biomed Chromatogr 20 (3), 282-293, 2006 | 154 | 2006 |
| The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML V Novotny-Diermayr, S Hart, KC Goh, A Cheong, LC Ong, H Hentze, ... Blood Cancer Journal 2 (5), e69, 2012 | 113 | 2012 |
| VS-5584, a novel and highly selective PI3K/mTOR kinase inhibitor for the treatment of cancer. S Hart, V Novotny-Diermayr, KC Goh, M Williams, YC Tan, LC Ong, ... Molecular cancer therapeutics, 2012 | 103* | 2012 |
| Discovery of Kinase Spectrum Selective Macrocycle (16 E)-14-Methyl-20-oxa-5, 7, 14, 26-tetraazatetracyclo [19.3. 1.1 (2, 6). 1 (8, 12)] heptacosa-1 (25), 2 (26), 3, 5, 8 (27 … AD William, ACH Lee, KC Goh, S Blanchard, A Poulsen, EL Teo, ... Journal of Medicinal Chemistry 55 (1), 169-196, 2011 | 103 | 2011 |
| Discovery of the Macrocycle (9 E)-15-(2-(Pyrrolidin-1-yl) ethoxy)-7, 12, 25-trioxa-19, 21, 24-triaza-tetracyclo [18.3. 1.1 (2, 5). 1 (14, 18)] hexacosa-1 (24), 2, 4, 9, 14 (26 … AD William, ACH Lee, A Poulsen, KC Goh, B Madan, S Hart, E Tan, ... Journal of Medicinal Chemistry 55 (6), 2623-2640, 2012 | 55 | 2012 |
| Forskolin: Genotoxicity assessment in Allium cepa KP Mohammed, A Aarey, S Tamkeen, P Jahan Mutation research/Genetic toxicology and environmental mutagenesis 777, 29-32, 2015 | 33 | 2015 |
| In vitro phase I cytochrome P450 metabolism, permeability and pharmacokinetics of SB639, a novel histone deacetylase inhibitor in preclinical species PR Venkatesh, E Goh, P Zeng, LS New, L Xin, MK Pasha, ... Biological and Pharmaceutical Bulletin 30 (5), 1021-1024, 2007 | 30 | 2007 |
| Preclinical metabolism and disposition of SB939 (Pracinostat), an orally active histone deacetylase inhibitor, and prediction of human pharmacokinetics R Jayaraman, VP Reddy, MK Pasha, H Wang, K Sangthongpitag, P Yeo, ... Drug metabolism and disposition 39 (12), 2219-2232, 2011 | 29 | 2011 |
| Pharmacodynamic evaluation of the target efficacy of SB939, an oral HDAC inhibitor with selectivity for tumor tissue V Novotny-Diermayr, N Sausgruber, YK Loh, MK Pasha, R Jayaraman, ... Molecular Cancer Therapeutics 10 (7), 1207-1217, 2011 | 26 | 2011 |
| Preclinical metabolism and pharmacokinetics of SB1317 (TG02), a potent CDK/JAK2/FLT3 inhibitor. MK Pasha, R Jayaraman, VP Reddy, P Yeo, E Goh, A Williams, KC Goh, ... | 23* | |
| 2-Anilino-4-aryl-8< i> H</i>-purine derivatives as inhibitors of PDK1 S Blanchard, CK Soh, CP Lee, A Poulsen, Z Bonday, KL Goh, KC Goh, ... Bioorganic & medicinal chemistry letters, 2012 | 15 | 2012 |
| Metabolism and disposition of pacritinib (SB1518), an orally active Janus kinase 2 inhibitor in preclinical species and humans R Jayaraman, MK Pasha, A Williams, K Cee Goh, K Ethirajulu Drug Metabolism Letters 9 (1), 28-47, 2015 | 13 | 2015 |
| Effect of 1-aminobenzotriazole on the in vitro metabolism and single-dose pharmacokinetics of chlorzoxazone, a selective CYP2E1 substrate in Wistar rats S Muzeeb, MK Pasha, SJS Basha, R Mullangi, NR Srinivas Xenobiotica 35 (8), 825-838, 2005 | 13 | 2005 |
| Pharmacokinetic/Pharmacodynamic (PK/PD) relationships of novel HDAC inhibitors in an HCT-116 mouse xenograft tumor model R Jayaraman, M Khalid Pasha, P Yeo, K Sangthongpitag, H Wang, ... AACR, 2009 | 1 | 2009 |
| Salt forms of amino pyrazine purine based selective kinase inhibitor FT Garzon US Patent 11,820,782, 2023 | | 2023 |
| Discovery of SB1317: A novel small molecule macrocycle with a unique kinase inhibitory spectrum in phase 1 clinical trials for hematological malignancies A William, S Blanchard, A Lee, A Poulsen, E Sun, EL Teo, H Nagaraj, ... Cancer Research 71 (8_Supplement), 3591-3591, 2011 | | 2011 |
| Design, synthesis and SAR studies leading to SB1518, a novel macrocyclic JAK2/FLT3 inhibitor in phase 2 clinical trials for myelofibrosis and lymphoma A Lee, A William, A Poulsen, E Tan, H Nagaraj, KL Goh, WC Ong, KC Goh, ... Cancer Research 71 (8_Supplement), 3564-3564, 2011 | | 2011 |
| The histone deacetylase inhibitor SB939 acts synergistically with Sorafenib in an orthotopic model of hepatucellular carcinoma V Novotny-Diermayr, K Sangthongpitag, MK Goh, YK Loh, LC Ong, ... Cancer Research 70 (8_Supplement), 5436-5436, 2010 | | 2010 |
| Novel potent and selective mTOR/PI3K inhibitors that inhibit tumor growth in animal models through efficient sustained shut down of the PI3K/Akt signaling pathway Z Bonday, M Williams, H Nagaraj, A Poulsen, H Hentze, DZ Chen, ... CANCER RESEARCH 69, 2009 | | 2009 |
